文献速递糖尿病

医疗补助扩展与降糖治疗使用的关系

Medicaid Expansion and Utilization of Antihyperglycemic Therapies.
PubMed 文献 · Diabetes Care · 2020-09-04

该研究采用双重差分设计分析2012-2017年州级医疗补助数据,比较扩展州(25个)与非扩展州(26个)在非胰岛素降糖治疗处方及费用上的差异,发现扩展州非胰岛素降糖治疗、SGLT2i和GLP-1RA的使用增长更快。

要点

  • 扩展州非胰岛素降糖治疗每千人季度增长率高于非扩展州。
  • 扩展州SGLT2i和GLP-1RA使用增长快于非扩展州。
  • 双重差分估计显示扩展州总体非胰岛素和GLP-1RA处方量显著增加。

核心结论

  • 医疗补助扩展州非胰岛素降糖治疗(含SGLT2i和GLP-1RA)使用增长显著高于非扩展州。

研究设计与样本

  • 采用双重差分设计,分析2012-2017年全国及州级医疗补助数据,比较扩展州(n=25)与非扩展州(n=26)的处方索赔与费用。

主要发现

  • 2014年扩展后,非胰岛素降糖治疗每州每千名参保人每季度平均增长:扩展州4.2%,非扩展州1.6%。
  • SGLT2i每千人季度增长率:扩展州125.3%,非扩展州87.6%。
  • GLP-1RA每千人季度增长率:扩展州20.7%,非扩展州16.0%。
  • 双重差分估计处方量变化:所有非胰岛素治疗1.68(95%CI 1.09-2.26;P<0.001),SGLT2i 0.125(-0.003至0.25;P=0.056),GLP-1RA 0.12(0.055-0.18;P<0.001)。

临床怎么用

  • 医疗补助扩展可能促进低收入糖尿病患者对非胰岛素降糖治疗的可及性。

局限性

  • 需要未来评估这些治疗可及性扩大对人群健康的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Certain antihyperglycemic therapies modify cardiovascular and kidney outcomes among patients with type 2 diabetes, but early uptake in practice appears restricted to particular demographics. We examine the association of Medicaid expansion with use of and expenditures related to antihyperglycemic therapies among Medicaid beneficiaries. RESEARCH DESIGN AND METHODS: We employed a difference-in-difference design to analyze the association of Medicaid expansion on prescription of noninsulin antihyperglycemic therapies. We used 2012-2017 national and state Medicaid data to compare prescription claims and costs between states that did (n = 25) and did not expand (n = 26) Medicaid by January 2014. RESULTS: Following Medicaid expansion in 2014, average noninsulin antihyperglycemic therapies per state/1,000 enrollees increased by 4.2%/quarter in expansion states and 1.6%/quarter in nonexpansion states. For sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA), quarterly growth rates per 1,000 enrollees were 125.3% and 20.7% for expansion states and 87.6% and 16.0% for nonexpansion states, respectively. Expansion states had faster utilization of SGLT2i and GLP-1RA than nonexpansion states. Difference-in-difference estimates for change in volume of prescriptions after Medicaid expansion between expansion versus nonexpansion states was 1.68 (95% CI 1.09-2.26; P < 0.001) for all noninsulin therapies, 0.125 (-0.003 to 0.25; P = 0.056) for SGLT2i, and 0.12 (0.055-0.18; P < 0.001) for GLP-1RA. CONCLUSIONS: Use of noninsulin antihyperglycemic therapies, including SGLT2i and GLP-1RA, increased among low-income adults in both Medicaid expansion and nonexpansion states, with a significantly greater increase in overall use and in GLP-1RA use in expansion states. Future evaluation of the population-level health impact of expanded access to these therapies is needed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Sumarsono A, Buckley LF, Machado SR, et al. Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care. 2020. PMID: 32887711. doi:10.2337/dc20-0735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。